- Home
- DQ vs BCYC Comparison
DQ vs BCYC Comparison
Compare DQ & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | BCYC |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 476.6M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DQ | BCYC |
|---|---|---|
| Price | $31.42 | $6.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $32.50 | $18.73 |
| AVG Volume (30 Days) | ★ 644.3K | 263.3K |
| Earning Date | 10-27-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $639,063,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $58.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $6.03 |
| 52 Week High | $36.59 | $15.47 |
Technical Indicators
Market Signals| Indicator | DQ | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 48.01 |
| Support Level | $31.06 | $6.73 |
| Resistance Level | $34.00 | $7.28 |
| Average True Range (ATR) | 1.53 | 0.35 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 17.97 | 28.26 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.